161 related articles for article (PubMed ID: 38431781)
1. Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer.
Wang C; Shi Q; Zhang G; Wu X; Yan W; Wan A; Xiong S; Yuan L; Tian H; Ma D; Jiang J; Qi X; Zhang Y
Oncologist; 2024 May; 29(5):e635-e642. PubMed ID: 38431781
[TBL] [Abstract][Full Text] [Related]
2. Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study.
Wang C; Yuan L; Wu X; Wang Y; Tian H; Zhang G; Wan A; Xiong S; Wang C; Zhou Y; Ma D; Bao Y; Qu M; Jiang J; Zhang Y; Qi X
BMC Med; 2024 Jun; 22(1):252. PubMed ID: 38886794
[TBL] [Abstract][Full Text] [Related]
3. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy.
Xu J; Ni C; Ma C; Zhang L; Jing X; Li C; Liu Y; Qu X
Clin Transl Oncol; 2017 Aug; 19(8):989-996. PubMed ID: 28247194
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer.
Kusama H; Kittaka N; Soma A; Taniguchi A; Kanaoka H; Nakajima S; Oyama Y; Seto Y; Okuno J; Watanabe N; Matsui S; Nishio M; Fujisawa F; Honma K; Tamaki Y; Nakayama T
Breast Cancer; 2023 Nov; 30(6):1085-1093. PubMed ID: 37782377
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
[No Abstract] [Full Text] [Related]
6. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.
Wu X; Tang P; Li S; Wang S; Liang Y; Zhong L; Ren L; Zhang T; Zhang Y
Nat Commun; 2018 Feb; 9(1):832. PubMed ID: 29483583
[TBL] [Abstract][Full Text] [Related]
7. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy.
Jia W; Yuan L; Ni H; Xu B; Zhao P
Technol Cancer Res Treat; 2021; 20():15330338211034291. PubMed ID: 34308689
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
Asano Y; Kashiwagi S; Onoda N; Noda S; Kawajiri H; Takashima T; Ohsawa M; Kitagawa S; Hirakawa K
Ann Surg Oncol; 2016 Apr; 23(4):1104-10. PubMed ID: 26511266
[TBL] [Abstract][Full Text] [Related]
10. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.
Chae S; Kang KM; Kim HJ; Kang E; Park SY; Kim JH; Kim SH; Kim SW; Kim EK
Curr Oncol; 2018 Apr; 25(2):e113-e119. PubMed ID: 29719435
[TBL] [Abstract][Full Text] [Related]
12. Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer.
Pang J; Zhou H; Dong X; Wang S; Xiao Z
Clin Breast Cancer; 2021 Dec; 21(6):e681-e687. PubMed ID: 34001439
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
Miao Y; Yan Q; Li S; Li B; Feng Y
Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
[TBL] [Abstract][Full Text] [Related]
15. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
Vernieri C; Mennitto A; Prisciandaro M; Huber V; Milano M; Rinaldi L; Cona MS; Maggi C; Ferrari B; Manoukian S; Mariani G; Bianchi G; Capri G; Rivoltini L; de Braud F
Sci Rep; 2018 Jun; 8(1):8703. PubMed ID: 29880896
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of the peripheral platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer patients.
Jin X; Wang K; Shao X; Huang J
Gland Surg; 2022 Jun; 11(6):1057-1066. PubMed ID: 35800742
[TBL] [Abstract][Full Text] [Related]
18. Correlation of serum NLR, PLR and HALP with efficacy of neoadjuvant chemotherapy and prognosis of triple-negative breast cancer.
Lou C; Jin F; Zhao Q; Qi H
Am J Transl Res; 2022; 14(5):3240-3246. PubMed ID: 35702128
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
[TBL] [Abstract][Full Text] [Related]
20. The relationship between platelet-lymphocyte ratio, neutrophil-lymphocyte ratio, and survival in metastatic gastric cancer on firstline modified docetaxel and cisplatinum plus 5 Fluorourasil Regimen: A single institute experience.
Dogan M; Eren T; Ozdemir N; Cigirgan CL; Zengin N
Saudi J Gastroenterol; 2015; 21(5):320-4. PubMed ID: 26458860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
